The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1517
Exablate Neuro for Essential Tremor
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved use of Exablate Neuro (Insightec) for unilateral thalamotomy to treat medication-refractory essential tremor in patients ≥22 years old. Exablate Neuro uses magnetic resonance-guided focused ultrasound (MRgFUS) to create lesions in the ventral intermediate nucleus of the thalamus. MRgFUS is also approved in the US for treatment of uterine fibroids and for pain palliation of bone metastases.

TREATMENT OF ESSENTIAL TREMOR — Essential tremor is a common neurological disorder that causes involuntary and rhythmic shaking, especially of the hand, head, neck, and voice. The tremor is not life threatening, but it can be distressing and make performance of everyday activities difficult. The most effective drugs used to treat essential tremor are the beta blocker propranolol (Inderal, and others) and (off-label) the anticonvulsant primidone (Mysoline, and generics); they ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Exablate Neuro for Essential Tremor
Article code: 1517c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian